Xanthic Biopharma Inc. (CSE:xTHC) (formerly Aurquest Resources Inc.) (“Xanthic” or the “Company”) is pleased to announce two of its executives, President Gary Galitsky, and Director Dr. Gunther Hintz, made a presentation on April 25, 2018 at a cannabis conference hosted by Bangkok’s Kasetsart University, Thailand’s largest university. The theme of the conference was to educate and teach the benefits of cannabinoid-based medicine, the history of herbal use and the future state of cannabis in the world.

Attendees included the Thai Minister of Health, Director of Drug Enforcement, Justice Minister, Minister of Agriculture, Pharmacological Head of Thailand and over 200 invited attendees, comprised of Thai doctors, pharmacists and medical practitioners. Xanthic was invited to participate in this event by Dr Samnouk, of iMed Therapy Co., Ltd., one of the leading biotechnology companies in Thailand, acting as a key consultant to the Thai government. Thailand has a population of 69 million and is the second largest economy in South East Asia.


Mr. Galitsky and Dr. Hintz presented an overview of Canadian cannabis legal history and the current Canadian legal landscape. Thailand is currently evaluating the decriminalization of cannabis and is looking at Canada as a “best-in-class” source for lessons and best practices.

In addition, Mr. Galitsky and Dr. Hintz introduced the audience to the Xanthic Biopharma patent-pending technology and the benefits of the Xanthic water-soluble THC and CBD product line.

Said Mr. Galitsky: “We are honoured to have been invited to speak at this conference. It is a great opportunity to have some involvement in the evolution of legal change in Thailand and to showcase the benefits of the Xanthic water soluble products. Although it is early days, we look forward to a time when we could create partnerships in Asia to expand the Xanthic footprint.”

About Xanthic
Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using a proprietary patent-pending process, Xanthic allows its strategic partners to deliver superior cannabinoid solubility, accurate micro-dosing, faster onset, increased bioavailability and improved consistency versus competitive infused products.

Through its investment in Avitas CBD Water, Xanthic has access to non-cannabis derived CBD infused products that qualify for distribution outside of the Cannabis dispensary network and into mainstream retail.

Click here to connect with Xanthic Biopharma Inc. and receive an Investor’s Presentation.

Source: www.newswire.ca

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less